轻型卒中或短暂性脑缺血发作后双联抗血小板治疗的出血风险
研究基于CHANCE-2试验的6412例携带CYP2C19功能丧失等位基因的轻型卒中或短暂性脑缺血发作患者,分析90天内出血事件及危险因素。结果显示250例(3.9%)发生出血,多集中在双联抗血小板治疗的21天内(200例,3.1%),以皮肤瘀斑、鼻出血和牙龈出血等轻微出血为主。替格瑞洛联合阿司匹林较氯吡格雷联合阿司匹林出血风险增高(HR=2.21,95%CI=1.68-2.89,p<0.001),当前吸烟与较低出血风险相关(HR=0.70,95%CI=0.52-0.95,p=0.02)。
要点
- 出血事件多发生于双联抗血小板治疗的21天内,且以轻微出血为主。
- 替格瑞洛联合阿司匹林较氯吡格雷联合阿司匹林增加出血风险(HR=2.21)。
- 替格瑞洛联合阿司匹林在年龄<65岁及无糖尿病患者中出血风险更高。
核心结论
- 出血事件大多发生在双联抗血小板治疗的21天阶段内,且一般较轻微。
- 非吸烟患者出血风险更高,替格瑞洛联合阿司匹林较氯吡格雷联合阿司匹林与出血风险增加相关,尤其在年龄<65岁和无糖尿病患者中。
研究设计与样本
- 研究纳入CHANCE-2试验的6412例携带CYP2C19功能丧失等位基因、在轻型卒中或短暂性脑缺血发作后接受双联抗血小板治疗的患者。
- 主要结局为90天内任何出血,采用GUSTO标准定义。
主要发现
- 共报告250例(3.9%)出血事件,其中200例(3.1%)发生在双联抗血小板治疗的21天内。
- 皮肤瘀斑、鼻出血和牙龈出血等轻微出血最为常见。
- 多变量分析显示,替格瑞洛联合阿司匹林较氯吡格雷联合阿司匹林与出血风险增加相关(HR=2.21,95%CI=1.68-2.89,p<0.001)。
- 当前吸烟与较低的出血风险相关(HR=0.70,95%CI=0.52-0.95,p=0.02)。
- 替格瑞洛联合阿司匹林较氯吡格雷联合阿司匹林在年龄<65岁患者中出血风险更高(HR=2.87,95%CI=1.95-4.22),在无糖尿病患者中出血风险更高(HR=2.65,95%CI=1.88-3.73;交互作用p值分别为0.04和0.03)。
关键数值与推荐
- 出血事件采用GUSTO标准定义。
- 替格瑞洛联合阿司匹林较氯吡格雷联合阿司匹林出血风险HR=2.21(95%CI=1.68-2.89,p<0.001)。
- 当前吸烟者出血风险HR=0.70(95%CI=0.52-0.95,p=0.02)。
- 年龄<65岁患者中替格瑞洛联合阿司匹林较氯吡格雷联合阿司匹林出血风险HR=2.87(95%CI=1.95-4.22)。
- 无糖尿病患者中替格瑞洛联合阿司匹林较氯吡格雷联合阿司匹林出血风险HR=2.65(95%CI=1.88-3.73)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study was undertaken to identify the risk of bleeding events and potential risk factors within 90 days in patients who carried CYP2C19 loss-of-function alleles and received dual antiplatelet therapy after minor stroke or transient ischemic attack. METHODS: A total of 6,412 patients were enrolled from the CHANCE-2 (Clopidogrel with Aspirin in High-Risk Patients with Acute Non-disabling Cerebrovascular Events II) trial. The main outcome was any bleeding within 90 days defined by the criteria from GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries). RESULTS: A total of 250 (3.9%) bleeding events were reported, which occurred mainly within the 21 days of dual antiplatelet therapy (200 cases, 3.1%). Minor bleeding of the skin bruises, epistaxis, and gum bleeding were most frequent. Multivariate analysis showed that treatment with ticagrelor-aspirin compared with clopidogrel-aspirin was associated with increased bleeding (hazard ratio [HR] = 2.21, 95% confidence interval [CI] = 1.68-2.89, p < 0.001). Current smoking was associated with a lower risk of bleeding (HR = 0.70, 95% CI = 0.52-0.95, p = 0.02). Additionally, ticagrelor-aspirin compared with clopidogrel-aspirin was associated with higher risk of bleeding in patients aged <65 years (HR = 2.87, 95% CI = 1.95-4.22) and those without diabetes mellitus (HR = 2.65, 95% CI = 1.88-3.73; p for interaction = 0.04 and 0.03, respectively). INTERPRETATION: Bleeding events mostly occurred within the 21-day dual antiplatelet therapy stage and were generally mild. The risk of bleeding was greater in nonsmoking patients, and was associated with treatment with ticagrelor-aspirin compared with clopidogrel-aspirin, particularly in patients aged <65 years and nondiabetic patients. ANN NEUROL 2022;91:380-388.
引用
- Wang A, Meng X, Tian X, et al. Bleeding Risk of Dual Antiplatelet Therapy after Minor Stroke or Transient Ischemic Attack. Ann Neurol. 2022. PMID: 34951042. doi:10.1002/ana.26287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。